Journal
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
Volume 13, Issue 1, Pages 15-30Publisher
OXFORD UNIV PRESS
DOI: 10.1017/S1461145709000182
Keywords
Citalopram; depression with atypical features; STAR*D
Funding
- National Institute of Mental Health, National Institutes of Health [N01MH90003]
- Eli Lilly
- GlaxoSmithKline
- Organon
- Pfizer
- New York State Office of Mental Health
- Research Foundation for Mental Hygiene (New York State)
- NARSAD
- National Institute of Mental Health
- National Institute on Alcohol Abuse and Alcoholism
- Lipha Pharmaceuticals
- Abbott Laboratories
- Alkermes
- Aspect Medical Systems
- AstraZeneca
- Bristol-Myers Squibb Company
- Cephalon
- Forest Pharmaceuticals Inc.
- J & J Pharmaceuticals
- Lichtwer Pharma GmbH
- Lorex Pharmaceuticals
- Novartis
- PamLab
- LLC
- Pfizer Inc
- Pharmavite
- Roche
- Sanofi/Synthelabo
- Solvay Pharmaceuticals Inc.
- Wyeth-Ayerst Laboratories
- Cyberonics
- National Institutes of Health
- Sepracor
- West Coast College of Biological Psychiatry
- Cederroth
- Cyberonics Inc.
- Janssen Pharmaceutica
- Lichtwer Pharma
- National Alliance for Research in Schizophrenia and Depression
- Stanley Foundation
- Abbott Laboratories Inc.
- Abdi Brahim
- Agency for Healthcare Research and Quality (AHRQ)
- Akzo (Organon Pharmaceuticals Inc.)
- Bayer
- Cephalon Inc.
- Corcept Therapeutics Inc.
- Fabre Kramer Pharmaceuticals Inc.
- Forest Pharmaceuticals
- LP
- Johnson Johnson PRD
- Meade Johnson
- Merck
- National Institute on Drug Abuse
- Neuronetics
- Parke-Davis Pharmaceuticals Inc.
- Pharmacia Upjohn
- Predix Pharmaceuticals
- Targacept
- VantagePoint
Ask authors/readers for more resources
Depressed patients with atypical features have an earlier onset of depression, a more chronic course of illness, several distinctive biological and familial features, and a different treatment response than those without atypical features. The efficacy and tolerability of selective serotonin reuptake inhibitors (SSRIs) have not been fully evaluated in depression with atypical features. This report evaluates data from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study to determine whether depressed outpatients with and without atypical features respond differently to the SSRI citalopram. Treatment-seeking participants with non-psychotic major depressive disorder were recruited from primary- and psychiatric-care settings. The presence/absence of atypical features was approximated using baseline ratings on the 30-item Inventory of Depressive Symptomatology - Clinician-rated. Following baseline assessments, participants received citalopram up to 60 mg/d for up to 14 wk. Baseline socio-demographic and clinical characteristics, and treatment outcomes, were compared between participants with and without atypical features. Of the 2876 evaluable STAR*D participants, 541 (19%) had atypical features. Participants with atypical features were significantly more likely to be female, Younger, unemployed, have greater physical impairment, a younger age of depression onset, a longer index episode, greater depressive severity, and more concurrent anxiety diagnoses. Those with atypical features had significantly lower remission rates, although this difference was no longer present after adjustment for baseline differences. Depressed patients with atypical features are less likely to remit with citalopram than those without atypical features. This finding is probably due to differences in baseline characteristics other than atypical symptom features.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available